Sarepta Therapeutics
Develops Duchenne muscular dystrophy medicines and genetic therapies for rare diseases.
Something off on this page? Send us feedback.
Profile
Commercializes three PMO medicines for Duchenne muscular dystrophy alongside the AAV gene therapy ELEVIDYS. The business centers on rare genetic diseases and is refocusing development resources toward siRNA assets after a restructuring.
Commercial operations center on three PMO medicines for Duchenne muscular dystrophy and on ELEVIDYS, an AAV gene therapy. The company's modern commercial franchise grew from earlier RNA and antisense work, then expanded into genetic-medicine modalities for rare diseases.
The FDA label limits ELEVIDYS to ambulatory patients aged four and older with a confirmed DMD mutation, following a revision with a boxed warning for serious liver injury and acute liver failure. The PMO therapies have confirmatory-evidence dependencies, while development resources are being prioritized toward siRNA assets after the 2025 restructuring.
Company facts
Key statistics
Year to date −2.2% · Average volume (30d) 3.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | Morgan Stanley | Target | $165 | $25 | ||
| Jul 9, 2026 | Piper Sandler | Reiterate | Neutral | $16 | $20 | |
| Jul 9, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform | ||
| Jul 8, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform | $27 | |
| May 15, 2026 | Evercore ISI | Target | $179 | $19 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $0.22 | −$0.05 | −123.0% | $366.4M | $401.3M | +9.5% | +5.34% |
| May 6, 2026Q1 FY26 | $0.98 | $3.16 | +223.8% | $474.2M | $730.8M | +54.1% | −9.68% |
| Feb 25, 2026Q4 FY25 | −$1.03 | −$3.58 | −247.6% | $369.6M | $442.9M | +19.8% | −8.01% |
| Nov 3, 2025Q3 FY25 | $0.01 | −$0.13 | −1,400.0% | $391.4M | $399.4M | +2.0% | −33.74% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $744.9M | $611.1M | $399.4M | $442.9M | $730.8M | $401.3M | |
| Gross profit | $607.3M | $458.5M | $248.6M | $44.2M | $611.4M | $251.9M | |
| Operating income | −$300.4M | $115.6M | −$103.4M | −$411.6M | $358.4M | $13.3M | |
| Net income | −$447.5M | $196.9M | −$179.9M | −$282.8M | $331.0M | −$4.9M | |
| Diluted EPS | −$4.60 | $1.89 | −$1.80 | −$3.93 | $2.88 | −$0.05 | |
| Gross margin | 81.5% | 75.0% | 62.2% | 10.0% | 83.7% | 62.8% | |
| Operating margin | -40.3% | 18.9% | -25.9% | -92.9% | 49.0% | 3.3% |
Fiscal years (4-quarter sums)FY21 $701.9M · FY22 $933.0M · FY23 $1.24B · FY24 $1.90B · FY25 $2.20B
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $788.5M · Total debt $1.05B · Total assets $3.19B · Shareholders' equity $1.53B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 105.58M · Float 94.61M · 89.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 18.99M | 17.99% | 13F | Aug 7, 2026 |
| State Street Corporation | 8.92M | 8.40% | 13G | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 8.38M | 7.94% | 13F | Aug 13, 2026 |
| Two Sigma Investments, LP | 4.60M | 4.36% | 13F | Aug 14, 2026 |
| Vanguard Capital Management LLC | 4.59M | 4.35% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 12, 2026 | Stephen Mayo | director | −7,239 | $17.02 |
| Dec 16, 2025 | Ian Michael Estepan | officer: Chief Operating Officer | −13,187 | $22.31 |
Peers
- Dyne Therapeutics
Exon 51 DMD candidate with a submitted BLA
- REGENXBIO
Late-stage microdystrophin gene-therapy challenger in DMD
- Solid Biosciences
Microdystrophin gene-therapy candidate in Phase 3 DMD development
- Capricor Therapeutics
Late-stage DMD cell therapy for cardiac and skeletal muscle
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| Dyne Therapeutics | $25.07 | −0.04% | $4.68B | — | — | — | — |
| REGENXBIO | $9.65 | −0.21% | $499.4M | — | — | 2.9 | +405.7% |
| Solid Biosciences | $9.77 | −0.10% | $961.9M | — | — | — | — |
| Capricor Therapeutics | $9.64 | +0.41% | $551.5M | — | — | — | — |
| Median | — | — | 2.9 | +405.7% |